Millendo Therapeutics, Inc.

Soleno Therapeutics, Inc. has unveiled promising data from two Phase III studies of its Prader-Willi syndrome candidate a year after regulators were left dissatisfied with pivotal data that were limi

The odds seem against Levo Therapeutics, Inc. ’s carbetocin nasal spray getting an advisory committee endorsement for treatment of hyperphagia (unrelenting hunger) associated with Prader Willi syndro

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Agrees To Pay $1.8bn For GenMark

Soleno Therapeutics, Inc. 's hopes of marketing the first ever treatment for Prader-Willi syndrome (PWS) took another hit this week when the US Food and Drug Administration told the Californian pharma